When bladder cancer patients are well-informed by their physicians, they acknowledge that tobacco use was likely the cause of their disease. The finding comes from a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society. Patients with such knowledge may be more motivated to quit smoking, which could help prolong their lives.
According the American Cancer Society, in the United States about 74,000 new cases of bladder…Continue
Added by Peter Hofland, PhD on November 10, 2015 at 10:00am — No Comments
A study published in the February 24, 2015 issue of JAMA, the Journal of The American Medical Association, suggests that children with acute lymphoblastic leukemia who had a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine (Oncovin®/ Vincasar Pfs®).
Despite major advances over the last 2 decades, cancer remains the leading cause of death by disease in children in the United…Continue
Added by Peter Hofland, PhD on February 24, 2015 at 11:00am — No Comments
ONC201 is a small molecule inducer of the TRAIL gene under current investigation as a novel anticancer agent. The small molecule drug has a unique mechanism of action that causes significant anti-tumor activity in a variety of types of human cancer.
In an article published OnlineFirst on February 13, 2015 in Cancer Research, a journal published by the American Association for Cancer Research (AACR), Professor Wafik El-Deiry, MD, PhD, FACP, Co-Program Leader of Molecular…
Added by Peter Hofland, PhD on February 20, 2015 at 1:00pm — No Comments
A new analysis has found that many women with breast cancer lack knowledge about their illness, with minority patients less likely than white patients to know and report accurate information about their tumors’ characteristics.
Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings highlight the need to educate patients about their…Continue
Added by Peter Hofland, PhD on January 29, 2015 at 9:30am — No Comments
The U.S. Food and Drug Administration (FDA) has approved panitumumab (Vectibix®, Amgen) for use in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as first-line treatment in patients with wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC).
With an estimated number of 96,830 colon and 40,000…Continue
Added by Peter Hofland, PhD on May 23, 2014 at 5:30pm — No Comments
Just a little more than a week before the start of the 50th Annual Meeting of ASCO, the American Society of Clinical Oncology in Chicago, Il, the news landed on my desk that Selma Schimmel, founder and CEO of Vital Options International and an outspoken activist, patient advocate, respected radio talk show host and author had died, aged 59, from malignant psoas syndrome or MPS, a…Continue
Added by Peter Hofland, PhD on May 21, 2014 at 8:00pm — No Comments
One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending Congestive Heart Failure or CHF finds improved health outcomes. Hoever, the study suggests that less frequent screening than currently recommended may yield similar clinical benefit. The researchers, in a study published in the Annals of Internal Medicine, utilized a simulation-based…Continue
Added by Peter Hofland, PhD on May 19, 2014 at 3:00pm — No Comments
The majority of cancers today are detected on the macroscopic level, when the tumor already includes millions of cancer cells and the disease is starting to advance into a more mature phase. But what if we could diagnose cancer before it took hold- while it was still only affecting a few localized cells? It could be compared to putting a fire out while there are just a few sparks.
An international team of researchers, led by…Continue
Added by Peter Hofland, PhD on May 18, 2014 at 1:00pm — No Comments
A study published this week as an early online publication in Cancer Epidemiology, Biomarkers & Prevention shows that according to a recent comprehensive analysis of lung cancer rates for women around the world lung cancer rates are dropping in young women in many regions of the globe. The authors of the article suggest that their data points to the success of tobacco control efforts.
However, the data also shows that rates continue to increase among older women in many…Continue
Added by Peter Hofland, PhD on May 16, 2014 at 10:30pm — No Comments
Researchers from University Hospitals (UH) Case Medical Center's Seidman Cancer Center found that the presence of tumor-infiltrating lymphocytes, a type of white blood cell, ahead of treatment, may help predict response to platinum-based chemotherapy in women with triple-negative breast cancer. The data, which comes from the PrECOG 0105 trial, will be presented at the 50th annual meeting of the American Society for Clinical…Continue
Added by Peter Hofland, PhD on May 16, 2014 at 2:00pm — No Comments
A study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR) showed that young adults who smoked water pipes in hookah bars had elevated levels of nicotine, cotinine, tobacco-related cancer-causing agents, and volatile organic compounds or VOC in their urine, increasing their risk for cancer and other chronic diseases.
Commenting on the study, Gideon…Continue
Added by Peter Hofland, PhD on May 16, 2014 at 2:00pm — No Comments
Prostate cancer is the second most common cancer and the second leading cause of cancer-related death in men in the United States. Based on recent data, it is estimated that, in 2013, nearly 239,000 men will be diagnosed with prostate cancer, and nearly 30,000 men will die of the disease. Furthermore, it is estimated that approximately $11.9 billion is spent each year in the United States on prostate cancer treatment.
This is why findings by…Continue
Added by Peter Hofland, PhD on May 16, 2014 at 12:00pm — No Comments
During the upcoming annual meeting of the American Society of Clinical Oncology (ASCO), to be held May 30 - June 3, 2014, in Chicago, Il, results from the Phase III Resonate™ trial with Ibrutinib (PCI-32765, Imbruvica®; Pharmacyclics), will be featured in ten abstracts, including both company-sponsored research studies and…Continue
Added by Peter Hofland, PhD on May 15, 2014 at 7:30pm — No Comments
Circulating tumor cells or CTCs in bone marrow of early breast cancer patients predict a higher risk of relapse as well as poorer survival. To confirm, bone marrow biopsy, an invasive and painful procedure, is generally used to identify these circulating tumor cells. But according to a new study published May 15, 2014 in the Journal of the National Cancer Institute, it may be possible to identify…Continue
Added by Peter Hofland, PhD on May 15, 2014 at 10:00am — No Comments
Results from a new study conducted by researchers at the University of Pennsylvania's Basser Research Center for BRCA and the Abramson Cancer Center, the nation's only BRCA-focused research center, shows that breastfeeding, tubal ligation – also known as having one's "tubes tied" – and oral contraceptives may help lower the risk of ovarian cancer for some women with BRCA gene mutations. The findings, based on a comprehensive meta-analysis of 44 existing peer-reviewed studies, are…Continue
Added by Peter Hofland, PhD on May 14, 2014 at 1:30pm — No Comments
Despite many claims suggesting otherwise, inappropriate demands for diagnostics and treatment by cancer patient are few and very rarely lead to unnecessary tests and treatments from their health care providers. This is the conclusion based on new results from a study that will be presented by researchers from the Abramson Cancer Center (ACC) and the Perelman School of Medicine at the University of Pennsylvania during the 50th annual meeting of the…Continue
Added by Peter Hofland, PhD on May 14, 2014 at 1:00pm — No Comments
Each year, more than 440,000 Americans die from smoking. Eight million Americans live with at least one serious chronic disease from smoking. The cost to U.S economy is $193 billion a year, with nearly $96 billion in direct medical costs and an additional $97 billion in lost productivity. But change is looming on the horizon.
January 2014 marks the 50th anniversary of the first Surgeon General's report on Smoking and Health. On January 11, 1964, Luther L. Terry,…Continue
Added by Peter Hofland, PhD on January 10, 2014 at 2:30pm — No Comments
The PANcreatic Cancer RadioImmunotherapy Trial-1 (PANCRIT-1) starts its patient accrual phase. This trial is a double-blind, randomized study and will enroll approximately 440 patients with metastatic pancreatic cancer. A majority of patients will be recruited at clinical trial sites across the United States, with additional sites in Canada, Europe and Israel participating. Eligible patients will be randomized 2 to 1 to the treatment arm of 3 doses of 90Y-clivatuzumab tetraxetan (…Continue
Added by Peter Hofland, PhD on January 9, 2014 at 8:30pm — No Comments
The U.S. Food and Drug Administration (U.S.FDA) has approved trametinib (Mekinist®; Glaxosmithkline/GSK) for use in combination with dabrafenib (Tafinlar®;Glaxosmithkline/GSK) for the treatment of patients with unresectable melanoma or metastatic melanoma with BRAF V600E or V600K mutations. These mutations must be detected by an FDA-approved companion…Continue
Added by Peter Hofland, PhD on January 9, 2014 at 5:30pm — No Comments
An Independent Data Monitoring Committee (IDMC) unanimously recommended that the Phase III Resonate™ trial, a head-to-head comparison of Ibrutinib (PCI-32765, Imbruvica®; Pharmacyclics) versus ofatumumab, be stopped early because the primary and a key secondary endpoint of the study have been met.
Resonate is a randomized, multicenter, open-label Phase…Continue
Added by Peter Hofland, PhD on January 7, 2014 at 9:00pm — No Comments